PLRX vs. TNGX, EOLS, LBPH, ZNTL, ALXO, SAGE, ETNB, PRAX, OPK, and YMAB
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Tango Therapeutics (TNGX), Evolus (EOLS), Longboard Pharmaceuticals (LBPH), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Sage Therapeutics (SAGE), 89bio (ETNB), Praxis Precision Medicines (PRAX), OPKO Health (OPK), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Tango Therapeutics (NASDAQ:TNGX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
Pliant Therapeutics has a net margin of 0.00% compared to Pliant Therapeutics' net margin of -299.88%. Tango Therapeutics' return on equity of -35.08% beat Pliant Therapeutics' return on equity.
Tango Therapeutics has higher revenue and earnings than Pliant Therapeutics.
Pliant Therapeutics received 51 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 71.11% of users gave Pliant Therapeutics an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
Tango Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
In the previous week, Pliant Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 19 mentions for Pliant Therapeutics and 16 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.28 beat Pliant Therapeutics' score of -0.23 indicating that Pliant Therapeutics is being referred to more favorably in the news media.
79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 6.2% of Tango Therapeutics shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Tango Therapeutics presently has a consensus price target of $17.25, indicating a potential upside of 121.15%. Pliant Therapeutics has a consensus price target of $45.67, indicating a potential upside of 197.31%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Tango Therapeutics.
Summary
Pliant Therapeutics beats Tango Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
